CN104327140B - 噁唑烷酮-腺苷型多靶点抗菌化合物及其制法和用途 - Google Patents
噁唑烷酮-腺苷型多靶点抗菌化合物及其制法和用途 Download PDFInfo
- Publication number
- CN104327140B CN104327140B CN201410534171.2A CN201410534171A CN104327140B CN 104327140 B CN104327140 B CN 104327140B CN 201410534171 A CN201410534171 A CN 201410534171A CN 104327140 B CN104327140 B CN 104327140B
- Authority
- CN
- China
- Prior art keywords
- methyl
- base
- amine
- purine
- dihydroxytetrahydrofandn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LFJUZIPAFRFHDI-MCDZGGTQSA-O NC1=NC=NC2=C1[NH+]=CN2[C@@H]([C@@H]1O)O[C@H](CO)[C@H]1O.O=C1N=[C-]OC1 Chemical compound NC1=NC=NC2=C1[NH+]=CN2[C@@H]([C@@H]1O)O[C@H](CO)[C@H]1O.O=C1N=[C-]OC1 LFJUZIPAFRFHDI-MCDZGGTQSA-O 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims abstract description 10
- 239000004599 antimicrobial Substances 0.000 title claims description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 230000002924 anti-infective effect Effects 0.000 claims abstract description 3
- 229960005475 antiinfective agent Drugs 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 160
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 53
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 230000000844 anti-bacterial effect Effects 0.000 claims description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 20
- 239000003208 petroleum Substances 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 17
- -1 benzyloxycarbonyl group arylamine Chemical class 0.000 claims description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 10
- 238000010898 silica gel chromatography Methods 0.000 claims description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 8
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012044 organic layer Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- AMUANCWASJTQSZ-QZGGMDDJSA-O CC(C)=C([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C(N=CN=C2N)=C2[NH+]=C1)O.O=C1N=[C-]OC1 Chemical class CC(C)=C([C@H]([C@H]([C@H]1O)O)O[C@H]1N1C(N=CN=C2N)=C2[NH+]=C1)O.O=C1N=[C-]OC1 AMUANCWASJTQSZ-QZGGMDDJSA-O 0.000 claims description 7
- 125000003368 amide group Chemical group 0.000 claims description 7
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 5
- 239000012317 TBTU Substances 0.000 claims description 5
- YLNSNVGRSIOCEU-ZCFIWIBFSA-N [(2r)-oxiran-2-yl]methyl butanoate Chemical compound CCCC(=O)OC[C@H]1CO1 YLNSNVGRSIOCEU-ZCFIWIBFSA-N 0.000 claims description 5
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 5
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000005457 ice water Substances 0.000 claims description 5
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 claims description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 5
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 claims 1
- 102000018378 Tyrosine-tRNA ligase Human genes 0.000 claims 1
- 108700024145 Tyrosine-tRNA ligases Proteins 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract description 10
- 239000013641 positive control Substances 0.000 abstract description 8
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract description 5
- 229960004125 ketoconazole Drugs 0.000 abstract description 5
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 abstract description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 abstract description 4
- 229960003907 linezolid Drugs 0.000 abstract description 4
- 235000019371 penicillin G benzathine Nutrition 0.000 abstract description 4
- 229940056360 penicillin g Drugs 0.000 abstract description 4
- 230000002147 killing effect Effects 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract description 3
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 306
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 192
- 150000001412 amines Chemical class 0.000 description 103
- 238000005160 1H NMR spectroscopy Methods 0.000 description 96
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 25
- 239000000243 solution Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 241000254064 Photinus pyralis Species 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- FPNKFBJQRODHDV-DCJFZGGZSA-N (2r,3r,4s,5s)-2-(6-aminopurin-9-yl)-5-(1-hydroxy-2-methylprop-1-enyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](C(O)=C(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 FPNKFBJQRODHDV-DCJFZGGZSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- RLYQSPYNMCUCAJ-UHFFFAOYSA-N 1-dodecylpyridin-1-ium-4-carboxylic acid;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+]1=CC=C(C(O)=O)C=C1 RLYQSPYNMCUCAJ-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-L 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfonatoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoate Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C([O-])=O)\C1=CSC(N)=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-L 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- LCCLUOXEZAHUNS-UHFFFAOYSA-N [4-(6-aminopurin-9-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol Chemical compound C1=NC2=C(N)N=CN=C2N1C1OC(CO)C2OC(C)(C)OC21 LCCLUOXEZAHUNS-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- LFETXMWECUPHJA-UHFFFAOYSA-N methanamine;hydrate Chemical compound O.NC LFETXMWECUPHJA-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/19—Purine radicals with arabinosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410534171.2A CN104327140B (zh) | 2014-10-11 | 2014-10-11 | 噁唑烷酮-腺苷型多靶点抗菌化合物及其制法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410534171.2A CN104327140B (zh) | 2014-10-11 | 2014-10-11 | 噁唑烷酮-腺苷型多靶点抗菌化合物及其制法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104327140A CN104327140A (zh) | 2015-02-04 |
CN104327140B true CN104327140B (zh) | 2016-06-15 |
Family
ID=52401955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410534171.2A Active CN104327140B (zh) | 2014-10-11 | 2014-10-11 | 噁唑烷酮-腺苷型多靶点抗菌化合物及其制法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104327140B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040266666A1 (en) * | 2003-05-23 | 2004-12-30 | Fatheree Paul R. | Cross-linked glycopeptide-cephalosporin antibiotics |
CN1777577A (zh) * | 2003-01-08 | 2006-05-24 | 希龙公司 | 抗菌剂 |
CN101765585A (zh) * | 2007-06-12 | 2010-06-30 | 尔察祯有限公司 | 抗菌剂 |
WO2014012014A1 (en) * | 2012-07-13 | 2014-01-16 | Massachusetts Institute Of Technology | Methods and products related to protozoan disease |
-
2014
- 2014-10-11 CN CN201410534171.2A patent/CN104327140B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1777577A (zh) * | 2003-01-08 | 2006-05-24 | 希龙公司 | 抗菌剂 |
US20040266666A1 (en) * | 2003-05-23 | 2004-12-30 | Fatheree Paul R. | Cross-linked glycopeptide-cephalosporin antibiotics |
CN101765585A (zh) * | 2007-06-12 | 2010-06-30 | 尔察祯有限公司 | 抗菌剂 |
WO2014012014A1 (en) * | 2012-07-13 | 2014-01-16 | Massachusetts Institute Of Technology | Methods and products related to protozoan disease |
Non-Patent Citations (4)
Title |
---|
Ester and Hydroxamate Analogues of Methionyl and Isoleucyl Adenylates as Inhibitors of Methionyl-tRNA and Isoleucyl-tRNA Synthetases;Jeewoo Lee,等;《Bioorganic & Medicinal Chemistry Letters》;20011231;第11卷;961-964 * |
Molecular Recognition of Tyrosinyl Adenylate Analogues by Prokaryotic Tyrosyl tRNA Synthetases;Pamela Brown,等;《Bioorganic & Medicinal Chemistry》;19991231;第7卷;2473-2485 * |
The Effect of Systematic Structural Modifications on the Antibacterial Activity of Novel Oxazolidinones;Gábor Pintér,等;《Medicinal Chemistry》;20111231;第7卷(第1期);45-55 * |
氨酰tRNA合成酶抑制剂作为新型抗感染药物的研究进展;王庆,等;《现代生物医学进展》;20120131;第12卷(第3期);563-571 * |
Also Published As
Publication number | Publication date |
---|---|
CN104327140A (zh) | 2015-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11098061B2 (en) | MK2 inhibitors and uses thereof | |
ES2605848T3 (es) | Derivados de pirrolo-pirazol sustituidos como inhibidores de cinasa | |
JP6389926B2 (ja) | Cdk阻害剤 | |
US8981084B2 (en) | Oxadiazole HDAC inhibitors | |
EP2539335B1 (en) | Process for the preparation of isoxazoline derivatives | |
Hannoun et al. | Synthesis and antibacterial evaluation of a novel library of 2-(thiazol-5-yl)-1, 3, 4-oxadiazole derivatives against methicillin-resistant Staphylococcus aureus (MRSA) | |
EP3464274A1 (en) | Benzazepine dicarboxamide compounds with secondary amide function | |
US20060046990A1 (en) | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | |
EP3233835A1 (en) | Benzazepine sulfonamide compounds | |
CN105712998A (zh) | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 | |
CN101300226A (zh) | 对组蛋白脱乙酰酶具有抑制活性的烷基氨甲酰基萘氧基辛烯酰基羟基酰胺衍生物及其制备方法 | |
BRPI0714722A2 (pt) | tetraidrofuro[3,2-b]pirrol-3-onas como inibidores de catepsina k | |
Ravichandiran et al. | Synthesis, molecular docking and antibacterial evaluation of 2-(4-(4-aminophenylsulfonyl) phenylamino)-3-(thiophen-2-ylthio) naphthalene-1, 4-dione derivatives | |
CN104327140B (zh) | 噁唑烷酮-腺苷型多靶点抗菌化合物及其制法和用途 | |
WO2001014346A1 (en) | Macrocyclic compounds and preparation methods thereof | |
JPS6335571A (ja) | 抗生物質の中間体 | |
DK2897970T3 (en) | MACROLIDE DERIVATIVES, PREPARING thereof, AND THERAPEUTIC APPLICATION | |
CN103910737A (zh) | 手性的1,4-二氢吡喃(2,3-c)吡唑衍生物及其合成方法和应用 | |
Panigrahi et al. | Synthesis, antimicrobial evaluation and molecular docking studies of novel Oxazolidinone-thiophene chalcone hybrid derivatives | |
Solankee et al. | Antibacterial evaluation of some novel 5-imidazolones | |
CN107428730A (zh) | 作为抗癌试剂的新型1,3,5‑三嗪基pi3k抑制剂及其制备方法 | |
CN104341475A (zh) | 利奈唑胺-腺苷型多靶点抗菌化合物及其制法和用途 | |
CN104341476A (zh) | 利奈唑胺-肌苷型多靶点抗菌化合物及其制法和用途 | |
CN104262433B (zh) | 噁二唑-腺苷型化合物作为TyrRS抑制剂及其制法和用途 | |
JP2006519234A (ja) | 新規化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Niu Yahong Inventor before: Xiao Zhuping Inventor before: Wei Wei Inventor before: Zeng Xiaotong Inventor before: Zhang Jirong |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171213 Address after: The green food of Wuhu Economic Development Zone in Anhui province Wuhu City Sanshan District 241000 Patentee after: Niu Yahong Address before: 416000 Hunan, Xiangxi Tujia and Miao Autonomous Prefecture, Jishou City People's road, No. 120 Patentee before: Jishou University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180523 Address after: 365000 Mingxi Economic Development Zone, Sanming City, Fujian Province, D District Patentee after: Fujian Bono Anke medical science and Technology Co.,Ltd. Address before: 241000 Anhui Wuhu Wuhu green food Economic Development Zone Patentee before: Niu Yahong |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20150204 Assignee: Fujian Fangxiao Biopharmaceutical Co.,Ltd. Assignor: Fujian Bono Anke medical science and Technology Co.,Ltd. Contract record no.: X2024350000020 Denomination of invention: Oxazolidinone adenosine type multi-target antibacterial compound and its preparation and application Granted publication date: 20160615 License type: Common License Record date: 20240229 |
|
EE01 | Entry into force of recordation of patent licensing contract |